SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
--------------
Date of Report (Date of earliest event reported): May 23, 2002
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 000-19319 04-3039129
(state or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
130 WAVERLY STREET
CAMBRIDGE, MA 02139
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 444-6100
--------------------------------------------------------------------------------
ITEM 5. OTHER EVENTS.
On May 23, 2002, Lynne H. Brum, the Company's Vice President of Corporate
Development and Communications, entered into a plan with Goldman, Sachs & Co.,
pursuant to which Goldman will undertake to sell, subject to a limit order, an
aggregate of 23,816 shares of the Company's stock issuable upon exercise of
options held by Ms. Brum. Sales under the plan are to begin no earlier than 90
days after adoption of the plan, and will take place at specified intervals
between August 29, 2002 and August 14, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: May 24, 2002 /s/ IAN F. SMITH
------------------------------------------
Vice President and Chief Financial Officer